NP_033973.2
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
33.9 kDa
NCBI Official Full Name
cytotoxic T-lymphocyte protein 4 isoform 1
NCBI Official Synonym Full Names
cytotoxic T-lymphocyte-associated protein 4
NCBI Protein Information
cytotoxic T-lymphocyte protein 4; CD152 antigen; cytotoxic T-lymphocyte-associated antigen 4
UniProt Protein Name
Cytotoxic T-lymphocyte protein 4
UniProt Synonym Protein Names
Cytotoxic T-lymphocyte-associated antigen 4; CTLA-4; CD_antigen: CD152
UniProt Synonym Gene Names
UniProt Entry Name
CTLA4_MOUSE
NCBI Summary for Ctla4
This gene is a member of the immunoglobulin superfamily, and encodes a protein that functions as a negative regulator of T-cell responses. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. [provided by RefSeq, Aug 2013]
UniProt Comments for Ctla4
CTLA-4: Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. Genetic variation in CTLA4 influences susceptibility to systemic lupus erythematosus (SLE). SLE is a chronic, inflammatory and often febrile multisystemic disorder of connective tissue. It affects principally the skin, joints, kidneys and serosal membranes. SLE is thought to represent a failure of the regulatory mechanisms of the autoimmune system. Genetic variations in CTLA4 may influence susceptibility to Graves disease, an autoimmune disorder associated with overactivity of the thyroid gland and hyperthyroidism. Genetic variation in CTLA4 is the cause of susceptibility to diabetes mellitus insulin-dependent type 12 (IDDM12). A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels. Genetic variation in CTLA4 is the cause of susceptibility to celiac disease type 3 (CELIAC3). It is a multifactorial disorder of the small intestine that is influenced by both environmental and genetic factors. It is characterized by malabsorption resulting from inflammatory injury to the mucosa of the small intestine after the ingestion of wheat gluten or related rye and barley proteins. In its classic form, celiac disease is characterized in children by malabsorption and failure to thrive. 4 isoforms of the human protein are produced by alternative splicing.
Protein type: Membrane protein, integral; Immunoglobulin superfamily
Cellular Component: Golgi apparatus; membrane; perinuclear region of cytoplasm; plasma membrane; integral to membrane; clathrin-coated endocytic vesicle; external side of plasma membrane
Biological Process: B cell receptor signaling pathway; negative regulation of T cell proliferation; immune system process; negative regulation of regulatory T cell differentiation; positive regulation of apoptosis; negative regulation of immune response; immune response; negative regulation of B cell proliferation; response to DNA damage stimulus
Research Articles on Ctla4
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with Ctla4 recombinant protein
Pathways associated with Ctla4 recombinant protein
Diseases associated with Ctla4 recombinant protein
Organs/Tissues associated with Ctla4 recombinant protein
|